Corporate Office

2223 Avenida de la Playa

Suite 206

La Jolla, CA 92037

+1 858 203 1169

Laboratory

3550 General Atomics Ct.

Bldg G02, #137

San Diego, CA 92121

+1 858 203 1168

Abreos France

232 Boulevard de Sainte Marguerite

13009 Marseille, France

+33 06 07 54 58 25

Executive Leadership Team

Brad.png

Dr. Bradley Messmer an  experienced entrepreneur in commercializing translational research in regional and international markets. After making seminal contributions to understanding the immunobiology and pathophysiology of chronic lymphocytic leukemia during his postdoctoral training, Dr. Messmer’s work has become highly multidisciplinary utilizing molecular biology, immunology, genomics, and nanotechnology to confront problems in oncology and immunotherapy.

The core technology of Abreos, the Veritope Platform, was originally developed by Dr. Messmer to identify counterfeit medications has since been applied in other applications such as diagnostics, therapeutic drug monitoring, and bio-purificaiton.

Former Roles:

  • Faculty at UC San Diego Moores Cancer Center

  • Assistant Investigator at the Feinstein Institute for Medical Research

Chief Business Officer

BRADLEY MESSMER

michael williams.jpg

Michael Williams is a senior business leader in the pharmaceutical and biotech industry with a proven track record of leading and building high impact teams, successful product launches in multiple countries, commercial drug development, strategic marketing, business development and alliance management. 

 

As Chief Business Officer, Michael is responsible for establishing effective relationships with our investors and partners and executing all business and corporate development activities.

Former roles:

  • Chief Operating Officer, Intarcia Therapeutics

  • Head of Global Marketing, Takeda Pharmaceuticals

  • Vice President for Global Commercial Development, Pfizer

  • Vice President for European Marketing & Operations, Bristol Myers Squibb

Chief Business Officer

MICHAEL R. WILLIAMS

2018-10-26.png

Helen Jenkins is responsible for development operations, strategic planning and portfolio management. She has been most successful in lead operational roles with transitioning research projects into clinical development programs and managing development collaborations.

 

Helen has 30 years of drug development experience in biotechnology and 20 years working on a variety of clinical programs. Her track record is highlighted by a strong understanding of science, drug development, project management and regulatory affairs. 

Former Roles:

  • COO at Alkahest, Inc.

  • CFO Nuon Therapeutics

  • COO Tobira Therapeutics (acquired by Allergan)

  • SVP of Development Operations at Saegis Pharmaceuticals

  • Project Management and Manufacturing at Genentech

Chief Operating Officer

HELEN JENKINS